Patents by Inventor Marty Lehto

Marty Lehto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection of pathogenic abeta using an epitope protection assay
    Patent number: 9523697
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: December 20, 2016
    Assignee: PROMIS NEUROSCIENCES Inc.
    Inventors: Neil Cashman, Marty Lehto
  • DETECTION OF PATHOGENIC POLYPEPTIDES USING AN EPITOPE PROTECTION ASSAY
    Publication number: 20110124018
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.
    Type: Application
    Filed: October 22, 2010
    Publication date: May 26, 2011
    Applicant: AMORFIX LIFE SCIENCES LTD.
    Inventors: Neil Cashman, Marty Lehto
  • Epitope protection assay and method for detecting protein conformations
    Publication number: 20070003977
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.
    Type: Application
    Filed: August 20, 2004
    Publication date: January 4, 2007
    Applicant: Amorfix Life Sciences Ltd
    Inventors: Neil Cashman, Marty Lehto